Skip to main content
NVDA-2.20%AAPL+2.47%GOOGL+0.41%MSFT+0.45%AMZN+0.20%TSM-0.95%SPCX+2.27%AVGO-0.23%META-0.29%TSLA-0.55%SKHY-3.91%MU-4.61%BRK-B-0.13%LLY+0.29%JPM-0.55%WMT+0.13%AMD-2.90%V0.00%XOM+0.67%ASMLa-1.66%JNJ-0.14%INTC-4.65%MA-0.34%0700.HK-1.94%1398.HK+0.79%ORCL-3.13%ABBV+0.58%BAC-0.61%CSCO-0.87%CVX-0.12%COST+0.09%KO+0.93%LRCX-4.74%CAT-1.65%AP2d-1.55%0005.HK-0.78%AMAT-2.40%UNH-0.33%HSBA.L-1.30%DELL-3.52%PG-0.07%MS-0.55%GE-0.51%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.25%HD-1.31%0939.HK+1.66%GS-0.71%NZDJPY-2.51%AUDJPY-1.77%CHFJPY-1.56%NZDCAD-1.40%EURNZD+1.34%GBPNZD+1.31%NZDUSD-1.28%USDJPY-1.27%EURJPY-1.21%GBPJPY-1.21%CADJPY-1.13%NZDCHF-0.98%USDZAR+0.90%USDNOK+0.85%USDSEK+0.84%EURZAR+0.78%AUDNZD+0.77%EURNOK+0.73%GBPZAR+0.72%EURSEK+0.72%AUDCAD-0.67%CHFNOK+0.60%AUDDKK-0.59%CHFSEK+0.59%EURAUD+0.56%GBPAUD+0.54%USDTHB+0.53%AUDUSD-0.51%AUDSGD-0.49%USDMXN+0.43%CADCHF+0.42%GBPTRY+0.41%NOKJPY-0.38%USDPLN+0.37%EURCHF+0.34%GBPCHF+0.34%NZDSGD-0.33%GBPHKD+0.32%USDCHF+0.31%GBPMXN-0.28%SGDJPY+0.25%EURPLN+0.24%USDSGD+0.22%AUDCHF-0.21%USDILS+0.16%NZDMXN-0.14%AUDNOK+0.14%EURHKD-0.13%USDCAD-0.12%USDDKK+0.12%PLNJPY+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%EURCAD-0.09%USDCNH+0.08%EURCZK-0.08%GBPUSD+0.05%EURUSD+0.04%USDCOP-0.04%GBPSGD+0.03%CHFSGD-0.03%EURCNH-0.02%EURGBP+0.02%USDHKD+0.01%EURDKK0.00%XPTUSD-5.48%UKOIL+4.70%HG1-4.42%GAGUSD-4.41%XAGUSD-4.41%USOIL+4.32%GAUUSD-0.86%XAUUSD-0.86%COTTON+0.84%S1+0.62%COFFEE-0.45%XNGUSD+0.40%BTCUSD-1.43%ETHUSD-0.77%USDTUSD-0.03%XRPUSD-2.97%SOLUSD-1.84%TRXUSDT-0.03%ZECUSDT-8.96%DOGEUSD-3.07%XMRUSDT-1.30%LINKUSD-1.61%XLMUSD-2.13%BCHUSDT-9.79%LTCUSD-1.81%UNIUSD-2.69%TONUSD+24.88%HBARUSDT-2.50%SUIUSD-3.99%TAOUSDT-5.12%AAVEUSD-2.93%DOTUSDT-3.07%ICPUSDT-2.16%ONDOUSDT-3.62%WLDUSDT-3.39%ATOMUSDT-3.78%ARBUSDT-1.07%JUPUSDT-4.67%INJUSDT-4.10%STXUSDT-4.53%FETUSDT-4.10%TIAUSDT-2.18%PYTHUSDT-1.58%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.37%WIFUSDT-5.38%OPUSDT-3.00%POLUSDT-4.92%IOTAUSDT-4.20%AXSUSDT-2.47%FARTCOINUSDT-4.23%EOSUSDT-3.15%DYDXUSDT-2.98%ORDIUSDT-1.84%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.20%AAPL+2.47%GOOGL+0.41%MSFT+0.45%AMZN+0.20%TSM-0.95%SPCX+2.27%AVGO-0.23%META-0.29%TSLA-0.55%SKHY-3.91%MU-4.61%BRK-B-0.13%LLY+0.29%JPM-0.55%WMT+0.13%AMD-2.90%V0.00%XOM+0.67%ASMLa-1.66%JNJ-0.14%INTC-4.65%MA-0.34%0700.HK-1.94%1398.HK+0.79%ORCL-3.13%ABBV+0.58%BAC-0.61%CSCO-0.87%CVX-0.12%COST+0.09%KO+0.93%LRCX-4.74%CAT-1.65%AP2d-1.55%0005.HK-0.78%AMAT-2.40%UNH-0.33%HSBA.L-1.30%DELL-3.52%PG-0.07%MS-0.55%GE-0.51%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.25%HD-1.31%0939.HK+1.66%GS-0.71%NZDJPY-2.51%AUDJPY-1.77%CHFJPY-1.56%NZDCAD-1.40%EURNZD+1.34%GBPNZD+1.31%NZDUSD-1.28%USDJPY-1.27%EURJPY-1.21%GBPJPY-1.21%CADJPY-1.13%NZDCHF-0.98%USDZAR+0.90%USDNOK+0.85%USDSEK+0.84%EURZAR+0.78%AUDNZD+0.77%EURNOK+0.73%GBPZAR+0.72%EURSEK+0.72%AUDCAD-0.67%CHFNOK+0.60%AUDDKK-0.59%CHFSEK+0.59%EURAUD+0.56%GBPAUD+0.54%USDTHB+0.53%AUDUSD-0.51%AUDSGD-0.49%USDMXN+0.43%CADCHF+0.42%GBPTRY+0.41%NOKJPY-0.38%USDPLN+0.37%EURCHF+0.34%GBPCHF+0.34%NZDSGD-0.33%GBPHKD+0.32%USDCHF+0.31%GBPMXN-0.28%SGDJPY+0.25%EURPLN+0.24%USDSGD+0.22%AUDCHF-0.21%USDILS+0.16%NZDMXN-0.14%AUDNOK+0.14%EURHKD-0.13%USDCAD-0.12%USDDKK+0.12%PLNJPY+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%EURCAD-0.09%USDCNH+0.08%EURCZK-0.08%GBPUSD+0.05%EURUSD+0.04%USDCOP-0.04%GBPSGD+0.03%CHFSGD-0.03%EURCNH-0.02%EURGBP+0.02%USDHKD+0.01%EURDKK0.00%XPTUSD-5.48%UKOIL+4.70%HG1-4.42%GAGUSD-4.41%XAGUSD-4.41%USOIL+4.32%GAUUSD-0.86%XAUUSD-0.86%COTTON+0.84%S1+0.62%COFFEE-0.45%XNGUSD+0.40%BTCUSD-1.43%ETHUSD-0.77%USDTUSD-0.03%XRPUSD-2.97%SOLUSD-1.84%TRXUSDT-0.03%ZECUSDT-8.96%DOGEUSD-3.07%XMRUSDT-1.30%LINKUSD-1.61%XLMUSD-2.13%BCHUSDT-9.79%LTCUSD-1.81%UNIUSD-2.69%TONUSD+24.88%HBARUSDT-2.50%SUIUSD-3.99%TAOUSDT-5.12%AAVEUSD-2.93%DOTUSDT-3.07%ICPUSDT-2.16%ONDOUSDT-3.62%WLDUSDT-3.39%ATOMUSDT-3.78%ARBUSDT-1.07%JUPUSDT-4.67%INJUSDT-4.10%STXUSDT-4.53%FETUSDT-4.10%TIAUSDT-2.18%PYTHUSDT-1.58%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.37%WIFUSDT-5.38%OPUSDT-3.00%POLUSDT-4.92%IOTAUSDT-4.20%AXSUSDT-2.47%FARTCOINUSDT-4.23%EOSUSDT-3.15%DYDXUSDT-2.98%ORDIUSDT-1.84%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%
ZT

Zevra Therapeutics, Inc. (ZVRA)

NASDAQ • Healthcare

$12.04
-$0.64 (-5.0%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$12.79
Previous Close$12.04
Day Range$12.02 - $12.79
Avg. Volume (3M)864.7K
Market Cap$712.9M
P/E Ratio12.5
52 Week Range
$7.16$15.04
Next EarningsIn 55 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$39.6M100%
Gross Profitminus cost of goods$38.1M96%
Operating Incomeminus R&D and overhead$16.7M42%
Net Incomeminus taxes and the rest$8.7M22%

In plain terms: out of every $100 in revenue, Zevra Therapeutics, Inc. keeps $22 as net profit.

Fundamentals & Financials

Revenue (TTM)
$136M
Net Income (TTM)
$58.2M
EPS (TTM)
$0.96
ROA (TTM)
19.25%
Current Ratio
5.17

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+316.7%Q1 2026$0.21
+900.0%Q2 2026$0.6
+27.3%Q3 2026$0.14
Next

Nov 4

in 55 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on medicines for rare diseases and other serious medical conditions. In FY2025, it generated $106.5 million in revenue from a portfolio that includes marketed therapies and development-stage central nervous system programs serving the United States.

Name
Zevra Therapeutics, Inc.
CEO
Neil F. McFarlane
Website
zevra.com
Industry
Healthcare
Year Founded
2006
Employees
61

Today's Snapshot

AI-generated

ZVRA is trading slightly higher at 12.05, in line with a flat sector.

Trading Volume

Below 10d avg (860.1K)

175K

vs S&P 500 Today

Outperforming Market

+0.64%

Updated: September 10, 2026 at 16:37 UTC

Technical Indicators

5 Buy2 Neutral1 Sell
ZVRA exhibits a buy bias with broad moving-average support and modest bullish momentum. The price at about $12 trades above the 50/100/200-day averages, and short- and mid-term SMAs also sit near or below the market, indicating overall price support. Momentum measures are mild—RSI in the low 50s and MACD slightly positive—while on-balance volume is constructive. ADX is low, suggesting the trend lacks strength, and ATR indicates moderate, contained volatility. Technical takeaway: Buy — price is supported by most major averages and volume, though trend strength remains limited.
All signals
  • EMA (5 indicators)$10.62 - $12.15
    Buy
  • RSI (14)53.25
    Neutral
  • Stochastic %K (14, 3, 3)59.38
    Neutral
  • MACD Level (12, 26)0.20
    Buy

Peers & Related Assets

CRVSCorvus Pharmaceuticals, Inc.
$13.33-4.3%
OLMAOlema Pharmaceuticals, Inc.
$10.36-5.7%
RIGLRigel Pharmaceuticals, Inc.
$47.22-0.3%
PRTAProthena Corporation plc
$9.3-2.5%
RGNXREGENXBIO Inc.
$8.73-0.3%
AKBAAkebia Therapeutics, Inc.
$0.95-7.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.